Success Metrics

Active Trials
0(0%)

Phase Distribution

Ph phase_1
2
67%

Phase Distribution

2

Early Stage

0

Mid Stage

0

Late Stage

Phase Distribution2 total trials
Phase 1Safety & dosage
2(100.0%)

Highest Phase Reached

Phase 1

Trial Status & Enrollment

Completion Rate

0.0%

0 of 0 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

3

all time

Status Distribution
Active(1)
Other(2)

Detailed Status

unknown2
Enrolling by invitation1

Development Timeline

Analytics

Development Status

Total Trials
3
Active
0
Success Rate
N/A
Most Advanced
Phase 1

Trials by Phase

Phase 12 (100.0%)

Trials by Status

unknown267%
enrolling_by_invitation133%

Recent Activity

0 active trials
Showing 3 of 3
enrolling_by_invitation

A Long Term Follow-Up Study for Subjects Who Have Received Q-Cells

NCT06163508
unknownphase_1

Study to Investigate the Safety of the Transplantation of Human Glial Restricted Progenitor Cells Into Subjects With Transverse Myelitis

NCT03887273
unknownphase_1

Study to Investigate the Safety of the Transplantation (by Injection) of Human Glial Restricted Progenitor Cells (hGRPs; Q-Cells®) Into Subjects With Amyotrophic Lateral Sclerosis (ALS)

NCT02478450

Clinical Trials (3)

Showing 3 of 3 trials
NCT06163508

A Long Term Follow-Up Study for Subjects Who Have Received Q-Cells

Enrolling By Invitation
NCT03887273Phase 1

Study to Investigate the Safety of the Transplantation of Human Glial Restricted Progenitor Cells Into Subjects With Transverse Myelitis

Unknown
NCT02478450Phase 1

Study to Investigate the Safety of the Transplantation (by Injection) of Human Glial Restricted Progenitor Cells (hGRPs; Q-Cells®) Into Subjects With Amyotrophic Lateral Sclerosis (ALS)

Unknown

All 3 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
3